{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:49:57Z","timestamp":1789487397323,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an acute immune-mediated peripheral neuropathy characterized by rapidly progressive symmetric limb weakness and diminished tendon reflexes, which may be complicated by respiratory muscle paralysis in severe cases. Current first-line treatments primarily consist of intravenous immunoglobulin (IVIg) and plasma exchange (PE), but approximately 20% of patients have an incomplete response to standard therapies. Additionally, issues such as limited supply of blood products, adverse reactions, and contraindications may limit conventional treatments. Efgartigimod alfa is an engineered human IgG1 Fc fragment that targets the neonatal Fc receptor (FcRn) and competitively inhibits FcRn-mediated lgG recycling, thereby promoting the lysosomal degradation of circulating IgG, including pathogenic IgG autoantibodies, and reducing serum IgG levels. Intravenous efgartigimod alfa is approved for AChR antibody-positive generalized myasthenia gravis (gMG), whereas the U.S. approval for chronic inflammatory demyelinating polyneuropathy (CIDP) applies to the subcutaneous efgartigimod alfa\/hyaluronidase co-formulation. Neither formulation is currently approved for GBS. Because IgG-mediated autoimmunity contributes to the pathogenesis of a subset of GBS, FcRn blockade provides a biologically plausible therapeutic strategy; however, its relevance may vary according to the underlying immunopathology. This narrative review summarizes the mechanistic rationale, preliminary clinical evidence, and available safety observations regarding efgartigimod in GBS, critically evaluates the limitations of the current evidence, and discusses unresolved questions and priorities for future research.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1952646","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:24:00Z","timestamp":1789482240000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efgartigimod for Guillain-Barr\u00e9 syndrome: rationale, clinical evidence, and future perspectives"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Wang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enwu","family":"Long","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Southwest Medical University","place":["Luzhou, China"]},{"name":"Department of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barre syndrome: Pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2018.09.025","article-title":"The electrodiagnosis of Guillain-Barre syndrome subtypes: Where do we stand","volume":"129","author":"Uncini","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub6","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"2014","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barre syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314862","article-title":"Treatment dilemmas in Guillain-Barre syndrome","volume":"88","author":"Verboon","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B9","unstructured":"FDA Approves Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults\n          \n          \n          \n          2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000451","article-title":"Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease","volume":"24","author":"Jaffry","year":"2023","journal-title":"J Clin Neuromuscul Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17562864261419026","article-title":"Efgartigimod for Guillain-Barre syndrome: A retrospective analysis of efficacy and safety","volume":"19","author":"Bi","year":"2026","journal-title":"Ther Adv Neurol Disord"},{"key":"B12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s13023-025-04060-0","article-title":"Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barre syndrome","volume":"20","author":"Zhang","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1734853","article-title":"Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barre syndrome: A retrospective study","volume":"17","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barre syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70308","article-title":"Efgartigimod as add-on treatment in refractory Guillain-Barre syndrome: A case report","volume":"32","author":"Ripellino","year":"2025","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1186\/s12883-025-04412-0","article-title":"Efgartigimod for treating Guillain-Barre syndrome with poor response to intravenous immunoglobulin: A case report","volume":"25","author":"Hu","year":"2025","journal-title":"BMC Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/119.6.2053","article-title":"The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients","volume":"119","year":"1996","journal-title":"Brain"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/jns.70072","article-title":"Intravenous efgartigimod or intravenous immunoglobulin in Guillain-Barre syndrome: An observational multicenter study","volume":"30","author":"Cai","year":"2025","journal-title":"J Peripher Nerv Syst"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14128","DOI":"10.1038\/s41598-026-44163-7","article-title":"Rapid neurological recovery in Guillain-Barre syndrome treated with efgartigimod","volume":"16","author":"Cheng","year":"2026","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces Iggs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25266","article-title":"Anti-ganglioside antibodies in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients","volume":"55","author":"Fan","year":"2017","journal-title":"Muscle Nerve"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barre syndrome: A multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"Lancet Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12646","article-title":"Efficacy and safety of eculizumab in Guillain-Barre syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial","volume":"29","author":"Kuwabara","year":"2024","journal-title":"J Peripher Nerv Syst"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5114\/polp.2025.151842","article-title":"Reviving hope \u2013 The journey of diagnosing and treating Guillain-Barr\u00e9 syndrome","volume":"100","author":"Oleszczuk","year":"2025","journal-title":"Pediatria Polska"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jca.70148","article-title":"Beyond the centrifuge: Is FcRn Inhibition Ready to Replace Apheresis in Treatment of Guillain-Barre Syndrome","volume":"41","author":"Kang","year":"2026","journal-title":"J Clin Apher"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-020-0616-8","article-title":"Newer immunotherapies for the treatment of acute neuromuscular disease in the critical care unit","volume":"22","author":"Patel","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2023.62.02.19","article-title":"Refractory Guillain-Barre syndrome in a patient with asymptomatic multiple myeloma successfully treated with low-dose rituximab","volume":"62","author":"Krecak","year":"2023","journal-title":"Acta Clin Croat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1348304","article-title":"Case report: Resolution of Guillain-Barre syndrome in a patient with dual primary tumors after treatment with rituximab","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Neurol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10646-y","article-title":"Efficacy of rituximab treatment in chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis","volume":"269","author":"Hu","year":"2022","journal-title":"J Neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1823319","article-title":"Clinical outcomes and safety of efgartigimod in Guillain-Barr\u00e9 syndrome: A retrospective observation study","volume":"17","author":"Tao","year":"2026","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001446.pub5","article-title":"Corticosteroids for guillain-barre syndrome","volume":"10","author":"Hughes","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578712","article-title":"Efficacy of FcRn antagonist efgartigimod in the treatment of Miller-Fisher\/Guillain-Barre overlap syndrome: Two case reports","volume":"407","author":"Fan","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040700","article-title":"Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report","volume":"103","author":"Zhou","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586663","article-title":"Efgartigimod in the treatment of Guillain-Barre syndrome: Case report","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1729694","article-title":"Case report: Guillain-Barre syndrome temporally associated with levofloxacin exposure and improvement following efgartigimod treatment","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of Guillain-Barre syndrome: A case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28277","article-title":"Efgartigimod alfa-fcab use in a pregnant woman with generalized myasthenia gravis: A case report","volume":"70","author":"Verity","year":"2024","journal-title":"Muscle Nerve"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16346","article-title":"Guillain-Barre syndrome: History, pathogenesis, treatment, and future directions","volume":"31","author":"Hughes","year":"2024","journal-title":"Eur J Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250336","article-title":"Expanding our understanding of Guillain-Barr\u00e9 syndrome: Recent advances and clinical implications","volume":"54","author":"Ripellino","year":"2024","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0165-5728(94)00190-Y","article-title":"IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses","volume":"58","author":"Ogino","year":"1995","journal-title":"J Neuroimmunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1021\/bi000749m","article-title":"Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor","volume":"39","author":"West","year":"2000","journal-title":"Biochemistry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1952646\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:24:04Z","timestamp":1789482244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1952646\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2026.1952646"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1952646","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1952646"}}